Skip to main content

Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial

Buy Article:

$50.00 plus tax (Refund Policy)

Abstract:

Bacterial vaginosis (BV) is the most prevalent vaginal infection worldwide and is characterized by depletion of the indigenous lactobacilli. Antimicrobial therapy is often ineffective. We hypothesized that probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 might provide an adjunct to antimicrobial treatment and improve cure rates. Sixty-four Brazilian women diagnosed with BV were randomly assigned to receive a single dose of tinidazole (2 g) supplemented with either 2 placebo capsules or 2 capsules containing L. rhamnosus GR-1 and L. reuteri RC-14 every morning for the following 4 weeks. At the end of treatment (day 28), the probiotic group had a significantly higher cure rate of BV (87.5%) than the placebo group (50.0%) (p = 0.001). In addition, according to the Gram-stain Nugent score, more women were assessed with “normal” vaginal microbiota in the probiotic group (75.0% vs. 34.4% in the placebo group; p = 0.011). This study shows that probiotic lactobacilli can provide benefits to women being treated with antibiotics for an infectious condition.

La vaginite bactérienne (VB) est l’infection vaginale la plus commune dans le monde et elle est caractérisée par une déplétion des lactobacilles indigènes. La thérapie antimicrobienne est souvent inefficace. Nous émettons l’hypothèse que les probiotiques Lactobacillus rhamnosus GR-1et Lactobacillus reuteri RC-14 puissent fournir un adjuvant au traitement antimicrobien et améliorer le taux de guérison. Soixante-quatre Brésiliennes souffrant de VB ont été choisies de façon aléatoire pour recevoir une seule dose de tinidazole (2 g) et 2 capsules de placebo ou 2 capsules contenant L. rhamnosus GR-1 et L. reuteri RC-14 à chaque matin pendant les 4 semaines suivantes. À la fin du traitement (28ième jour), le groupe avec probiotiques affichait un taux de guérison significativement plus élevé (87.5 %) comparativement au groupe placebo (50.0 %)(p = 0.0001). Aussi, selon le score de Nugent après coloration de Gram, plus de femmes ont été considérées porteuses d’une flore vaginale microbiotique normale dans le groupe avec probiotiques (75.0 % versus 34.4 % chez le groupe placebo; p = 0.011). Cette étude démontre que les lactobacilles probiotiques peuvent être bénéfiques aux femmes traitées avec des antibiotiques pour une condition infectieuse.

Document Type: Research Article

Publication date: February 1, 2009

More about this publication?
  • Published since 1954, this monthly journal contains new research in the field of microbiology including applied microbiology and biotechnology; microbial structure and function; fungi and other eucaryotic protists; infection and immunity; microbial ecology; physiology, metabolism and enzymology; and virology, genetics, and molecular biology. It also publishes review articles and notes on an occasional basis, contributed by recognized scientists worldwide.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • Ingenta Connect is not responsible for the content or availability of external websites

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Partial Open Access Content
Partial Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more